Efficacy

Talzenna (talazoparib) for Breast Cancer

Talzenna (talazoparib) is a poly ADP-ribose polymerase (PARP) inhibitor approved for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. This approval is contingent on the identification of BRCA mutations, with the efficacy of talazoparib being demonstrated in clinical trials specifically for this subgroup of breast cancer patients. In the pivotal EMBRACA trial, talazoparib significantly prolonged progression-free survival (PFS) compared to standard chemotherapy. Patients treated with talazoparib had a median PFS of 8.6 months, compared to 5.6 months for those receiving chemotherapy, indicating a robust clinical benefit for those with BRCA mutations.

Enhertu (fam-trastuzumab deruxtecan-nxki) for Breast Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that targets HER2-positive breast cancer, a type of cancer that tests positive for human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. Enhertu has shown substantial efficacy in this patient population. In a pivotal phase II study, DESTINY-Breast01, patients with HER2-positive metastatic breast cancer who had received two or more prior anti-HER2 therapies demonstrated a confirmed objective response rate (ORR) of 60.9% with Enhertu treatment. The median duration of response (DoR) was 14.8 months, highlighting the potential for long-term benefit.

Further supporting its efficacy, the phase III DESTINY-Breast03 trial compared Enhertu to trastuzumab emtansine (T-DM1) in patients with previously treated HER2-positive metastatic breast cancer. Enhertu significantly improved PFS, with a hazard ratio for disease progression or death of 0.28 compared to T-DM1. This marked improvement in PFS underscores Enhertu's role as a highly effective treatment option for patients with HER2-positive metastatic breast cancer.

In summary, both Talzenna and Enhertu have demonstrated significant efficacy in their respective subgroups of breast cancer patients. Talzenna has shown to be effective in prolonging PFS in patients with BRCA-mutated, HER2-negative breast cancer, while Enhertu has proven to be a potent option for those with HER2-positive metastatic breast cancer, improving ORR and PFS. These targeted therapies represent important advancements in the personalized treatment of breast cancer, offering hope for improved outcomes in these populations.